Acquired factor VII deficiency causing severe bleeding disorder secondary to AL amyloidosis of the liver

A 52 year-old male presented with neck pain after undergoing thyroidectomy for a goiter three weeks prior which was complicated by a neck hematoma requiring evacuation. Computed tomography (CT) scan showed a neck hematoma requiring evacuation and he received desmopressin with cessation of bleeding. Coagulation studies were normal. He returned eighteen months later with severe oral mucosal bleeding after a dental procedure and required transfusions with red blood cells, platelets, and fresh frozen plasma (FFP) in addition to desmopressin, Humate-P, aminocaproic acid, and surgical packing. A comprehensive bleeding diathesis workup was normal. He was readmitted six months later due to abdominal pain and distention and found to have massive hepatosplenomegaly on CT. A new coagulopathy workup revealed prolonged INR to 1.5, corrected prothrombin time mixing study, and a low factor VII level (29%), suggesting acquired factor VII deficiency. A transjugular liver biopsy revealed extensive involvement by ALamyloidosis- Kappa type. He then developed a large right retroperitoneal hematoma which required multiple transfusions with FFP, cryoprecipitate, aminocaproic acid, and vitamin K with slight success. Hemorrhage was subsequently stabilized with recombinant factor VIIa administered every four hours which corresponded with correction of factor VII levels and PT and eventual cessation hemorrhage. Acquired factor VII deficiency causing severe coagulopathy was attributed to hepatic amyloidosis ALkappa subtype. We started treatment with bortezomib, dexamethasone, and cyclophosphamide, however, the patient succumbed to uncontrolled hemorrhage. Acquired factor VII deficiency is extremely rare and to our knowledge, this is the only known case of factor VII deficiency secondary to amyloidosis involving the liver.

[1]  Giampaolo Merlini,et al.  Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[2]  K. Devreese,et al.  Isolated acquired factor VII deficiency: review of the literature , 2016, Acta clinica Belgica.

[3]  P. Hawkins,et al.  Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis. , 2014, Blood.

[4]  G. Merlini,et al.  Systemic light chain amyloidosis: an update for treating physicians. , 2013, Blood.

[5]  B. Hazenberg Amyloidosis: a clinical overview. , 2013, Rheumatic diseases clinics of North America.

[6]  M. Albayrak,et al.  Acquired Factor VII deficiency associated with pneumonia , 2011 .

[7]  G. Mariani,et al.  Factor VII Deficiency , 2009, Seminars in thrombosis and hemostasis.

[8]  B. Brenner,et al.  Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency , 2007, Hematology.

[9]  B. Grabensee,et al.  Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  Nomenclature Guidelines , 2006 .

[11]  C. Mullighan,et al.  Acquired isolated factor VII deficiency associated with severe bleeding and successful treatment with recombinant FVIIa (NovoSeven) , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[12]  K. Takenaka,et al.  Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. , 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[13]  M. Skinner,et al.  Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. , 2001, Blood.

[14]  K. Reddy,et al.  Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. , 1997, Gastroenterology.

[15]  U. Hedner,et al.  Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. , 1993, Transfusion medicine reviews.

[16]  L. Poller,et al.  Factor VII as a marker of hepatocellular synthetic function in liver disease. , 1976, Journal of clinical pathology.

[17]  Y. Dahlan,et al.  Liver Amyloidosis Complicated with Liver Failure: A Case Report and Review of the Literature , 2011 .